STOCK TITAN
  1. Home
  2. News
  3. PCSA

Processa Pharmaceuticals Inc - PCSA STOCK NEWS

Welcome to our dedicated news page for Processa Pharmaceuticals (Ticker: PCSA), a resource for investors and traders seeking the latest updates and insights on Processa Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Processa Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Processa Pharmaceuticals's position in the market.

News
Processa Pharmaceuticals Presents Two Abstracts at the AACR Annual Meeting 2024 Including New Data on the NGC-Cap Phase 1b Trial
Rhea-AI Summary
Processa Pharmaceuticals, Inc. presented Phase 1b data on its Next Generation Capecitabine (NGC-Cap) at the AACR Annual Meeting 2024. NGC-Cap showed greater 5-FU exposure and lower side effects compared to monotherapy capecitabine. The study aims to advance NGC-Cap into a Phase 2 trial in breast cancer with FDA support.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.35%
Tags
clinical trial
-
News
Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (PCSA) to present a corporate update at the MedInvest Biotech and Pharma Investor Conference. The focus is on developing advanced chemotherapeutic drugs for cancer patients, with George Ng, CEO, and David Young, President of R&D, participating. The event will take place on April 3-4, 2024, in New York.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.19%
Tags
conferences
-
News
Processa Pharmaceuticals to Present Data at the American Association for Cancer Research Annual Meeting
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) will present two posters at the American Association for Cancer Research Annual Meeting 2024, showcasing their innovative chemotherapeutic drugs. The posters highlight the advancements in drug safety and efficacy, with promising clinical trial results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.45%
Tags
conferences
News
Processa Pharmaceuticals to Present at the 2024 BIO CEO & Investor Conference
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (PCSA) will present a corporate update at the 2024 BIO CEO & Investor Conference in New York City. CEO George Ng will discuss the development of chemotherapeutic drugs for cancer patients. Investors can register for the conference and request one-on-one meetings with Mr. Ng.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.47%
Tags
conferences
-
News
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (PCSA) CEO George Ng to present a corporate update at The Winter Wrap-Up MicroCap Rodeo 2024 Virtual Conference. The company focuses on developing chemotherapeutic drugs for cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.43%
Tags
conferences
-
News
Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Market. The Company's ordinary shares maintained a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, achieving compliance on February 2, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
none
News
Processa Pharmaceuticals Announces Closing of $7.0 Million Public Offering
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has closed a public offering of 1,555,555 shares of common stock and common warrants, raising $7.0 million in gross proceeds. The offering price per share was $4.50, with the common warrants having an exercise price of $4.50 per share and a term of five years. H.C. Wainwright & Co., LLC acted as the exclusive placement agent for the offering. The registration statement on Form S-1 relating to the offering was declared effective by the SEC on January 26, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
offering
-
News
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has announced a public offering of 1,555,555 shares of common stock and common warrants, with a combined public offering price of $4.50 per share. The gross proceeds from the offering are expected to be $7.0 million. The common warrants will have an exercise price of $4.50 per share and a term of five years after their original issuance date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-28.04%
Tags
offering
-
News
Processa Pharmaceuticals Announces Successful Completion of Phase 1b Safety Evaluation of NGC-Cap in Patients with Advanced Cancer Resulting in Recommended Phase 2 Doses
Rhea-AI Summary
Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) successfully completed the safety tolerability evaluation in its Phase 1b trial of Next Generation Capecitabine (NGC-Cap), a cancer treatment metabolite. NGC-Cap provides 2-10 times greater exposure to its 5-FU metabolite than capecitabine administration, with better tolerance and positive preliminary efficacy results. The Phase 2 trial in advanced or metastatic breast cancer is based on the Phase 1b data, with NGC-Cap showing potential for improved efficacy and safety over capecitabine.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
148.78%
Tags
clinical trial
News
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
Rhea-AI Summary
Processa Pharmaceuticals, Inc. announces plans to expand the development of NGC-Cap into the treatment of advanced or metastatic breast cancer. The FDA agrees that existing data and studies can be used to support the Phase 2 breast cancer trial design, making the development a more efficient and straightforward path to approval. The expansion into breast cancer represents a larger market than colorectal cancer, with the potential to differentiate NGC-Cap from existing treatments for breast cancer. Processa plans to initiate the Phase 2 study in the third quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.84%
Tags
none
Stock PCSA logo
Processa Pharmaceuticals Inc

Nasdaq:PCSA

PCSA Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

PCSA Stock Data

4.77M
2.49M
11.27%
1.98%
1.25%
Heavy Duty Truck Manufacturing
Manufacturing
Link
United States
Hanover

About PCSA

processa pharmaceuticals was founded in october 2017 with a mission to develop products that can improve the survival and/or quality of life for patients who have a high unmet medical need. the company is headquartered in hanover, maryland.